Lipopeptide, preparation method of lipopeptide, lipopeptidyl lipid nano delivery system and application of lipopeptidyl lipid nano delivery system
By using lipopeptides formed by 1,2-epoxy compounds and lysine-histidine polypeptides and combining cholesterol and other components, a lipopeptide-based lipid nanodelivery system was prepared, which solved the lipid nanodelivery in existing RNA therapy The high toxicity and difficulty in targeting of the particle system have achieved efficient delivery and precise targeting of RNA molecules.
Patent Information
- Application Number
- CN202410893129.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-04
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-04
AI Technical Summary
The lipid nanoparticle system in existing RNA therapies has problems such as high production cost, high biotoxicity, strong immunogenicity, low endosomal escape efficiency and difficulty in targeting extrahepatic organs. It is especially difficult to effectively deliver macromolecular nucleic acids such as mRNA.
A lipopeptide-based lipid was prepared by using 1,2-epoxy compound and lysine-histidine polypeptide-based lipids by ring-opening reaction, and combined with cholesterol, auxiliary lipids and pegylated lipids. Nanodel delivery system, used to prepare lipopeptide-based lipid nanoparticles to achieve efficient delivery of RNA molecules.
Provides a low toxicity and simple preparation of lipopeptide-based lipid nanodelivery system, which can efficiently deliver siRNA, mRNA and other RNA molecules in vitro and in vivo, achieve high delivery efficiency in a variety of cell lines, and to liver, spleen or The lung organs are highly selective and achieve precise targeted delivery.
Smart Images

Figure CN118909033A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a lipopeptide and a preparation method thereof, a lipopeptide-based lipid nano-delivery system and applications thereof. Background Art
[0002] RNA therapy, which has emerged in recent years, is a treatment method that can manipulate gene expression or produce therapeutic proteins. It has been widely studied for the treatment of infectious diseases, cancer, immune diseases, neurodegenerative diseases, etc. Common small interfering RNA (siRNA) therapy is to reduce the expression of pathogenic genes in cells through RNA-induced silencing complex (RISC)-mediated mRNA (messenger RNA, mRNA) degradation to achieve therapeutic effects. The size of mRNA is much larger than that of siRNA. mRNA-based therapy achieves therapeutic purposes by enhancing the expression of therapeutic proteins in cells. However, regardless of the mechanism of therapeutic action, the anionic properties of RNA molecules and their sensitivity to RNases present in blood and tissues make it difficult for therapeutic RNA to effectively enter cells and exert its effects. In order to overcome the obstacles of RNA delivery in vivo and in vitro, scientists have developed various carrier systems to protect RNA from degradation so that it can be delivered to target cells to the maximum extent, thereby exerting therapeutic effects. Among them, the delivery system based on lipid nanoparticles (LNP) has attracted much attention. However, the currently developed LNP systems have the disadvantages of high production cost, high biological toxicity, strong immunogenicity, low efficiency of endosomal escape and difficulty in extrahepatic organ targeting. In addition, the currently developed mature LNP systems are mainly used for the delivery of small molecule nucleic acid siRNA, and the effective delivery of large molecule nucleic acids such as mRNA is still a problem. Summary of the invention
[0003] The present invention aims to solve at least one of the technical problems existing in the related art. To this end, the first object of the present invention is to provide a lipopeptide; the second object of the present invention is to provide a method for preparing a lipopeptide; the third object of the present invention is to provide a lipopeptide-based lipid nano-delivery system; the fourth object of the present invention is to provide an application of a lipopeptide-based lipid nano-delivery system.
[0004] In order to achieve the first purpose, the technical solution adopted by the present invention is: A lipopeptide, wherein the lipopeptide is a compound formed by a ring-opening reaction between a 1,2-epoxy compound and part or all of the exposed amino groups of a lysine-histidine polypeptide; Wherein, the structural formula of the lipopeptide is: or .
[0005] Furthermore, the 1,2-epoxy compound includes 2 to 22 carbon atoms.
[0006] Further, the 1,2-epoxy compound is any one of 1,2-epoxy-9-decene, 1,2-epoxydecane, 1,2-epoxydodecane, 1,2-epoxytetradecane and 1,2-epoxyoctadecane.
[0007] Furthermore, in the lipopeptide structural formula, the value range of x is 0-10, the value range of y is 1-10, the value range of n is 1-5, and the value range of m is 0-5.
[0008] Furthermore, in the lipopeptide structural formula, R is any one of the following structural formulas, or R is hydrogen and at least one R is any one of the following structural formulas: , , , and .
[0009] In order to achieve the second purpose, the technical solution adopted by the present invention is: A method for preparing a lipopeptide, for preparing the lipopeptide, comprises the following steps: S101. Under the protection of an inert gas, add a lysine-histidine polypeptide and 1,2-epoxide to a reaction solvent, and stir at a temperature of 50° C. to 110° C. for 48 h to 72 h to prepare a mixture; S102, purifying the mixture to prepare the lipopeptide.
[0010] In order to achieve the third purpose, the technical solution adopted by the present invention is: A lipopeptide-based lipid nano-delivery system, comprising the lipopeptide, and further comprising one of cholesterol and a cholesterol derivative, an auxiliary lipid and a PEGylated lipid; The molar ratio of lipopeptide, cholesterol or cholesterol derivative, auxiliary lipid and pegylated lipid is (5-45):(25-40):(25-65):(0.8-2.5).
[0011] Further, the auxiliary lipid is at least one of a cationic lipid, an anionic lipid, a phospholipid and a phospholipid derivative; The PEGylated lipid is at least one of PEG-DMG, PEG-C-DMG and PEG-DSPE.
[0012] In order to achieve the fourth purpose, the technical solution adopted by the present invention is: An application of a lipopeptide-based lipid nano-delivery system is used to prepare lipopeptide-based lipid nano-particles. The lipopeptide-based lipid nano-particles comprise the lipopeptide-based lipid nano-delivery system and RNA molecules.
[0013] Furthermore, the RNA molecule is at least one of messenger RNA, small interfering RNA, micro RNA and self-amplifying RNA; and the mass ratio of the lipopeptide-based lipid nano-delivery system to the RNA molecule is 40 to 10:1.
[0014] The above one or more technical solutions in the embodiments of the present invention have at least one of the following technical effects: The present invention provides a lipopeptide with low toxicity. The preparation process of the lipopeptide is simple. Based on the lipopeptide, the present invention also provides a lipopeptide-based lipid nano-delivery system and its application. The lipopeptide-based lipid nano-delivery system is used to prepare lipopeptide-based lipid nanoparticles. The lipopeptide-based lipid nanoparticles can achieve high-efficiency delivery of various RNA molecules such as siRNA and mRNA in vitro and in vivo. The results of in vitro experiments show that the lipopeptide-based lipid nanoparticles provided by the present invention can deliver RNA molecules in various cell lines to achieve high delivery efficiency; the results of in vivo experiments show that the lipopeptide-based lipid nanoparticles provided by the present invention have high selectivity for liver, spleen or lung organs, so it can achieve the purpose of accurately delivering RNA molecules in vivo to target multiple organs.
[0015] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 is C provided in Example 2 of the present invention 10 -KH 2 Transmission electron microscopy (TEM) image of / DOTAP (scale bar: 50 nm).
[0017] Figure 2 The LP-LNPs prepared by the lipopeptide and the auxiliary lipid DOTAP provided in Experimental Example 1 of the present invention and Lipofectamine 2000 TM Statistical graph of 24 h toxicity to A549 cells.
[0018] Figure 3 The LP-LNPs prepared by the lipopeptide and the auxiliary lipid DOPE provided in Experimental Example 1 of the present invention and Lipofectamine 2000 TM Statistical graph of 24 h toxicity to A549 cells.
[0019] Figure 4 The LP-LNPs prepared by the lipopeptide and the auxiliary lipid DSPC provided in Experimental Example 1 of the present invention and Lipofectamine 2000 TM Statistical graph of 24 h toxicity to A549 cells.
[0020] Figure 5 The LP-LNPs prepared by the lipopeptide and the auxiliary lipid 14PA provided in Experimental Example 1 of the present invention and Lipofectamine 2000 TM Statistical graph of 24 h toxicity to A549 cells.
[0021] Figure 6 This is a statistical graph of the gene silencing efficiency of LP-LNPs prepared by the lipopeptide and the auxiliary lipid DOTAP provided in Experimental Example 1 of the present invention in delivering siCCNB1 to A549 cells.
[0022] Figure 7 This is a statistical graph of the gene silencing efficiency of LP-LNPs prepared by the lipopeptide provided in Experimental Example 1 of the present invention and the auxiliary lipid DOPE in delivering siCCNB1 to A549 cells.
[0023] Figure 8 This is a statistical graph of the gene silencing efficiency of LP-LNPs prepared by the lipopeptide and auxiliary lipid DSPC provided in Experimental Example 1 of the present invention in delivering siCCNB1 to A549 cells.
[0024] Fig. 9 This is a statistical graph of the gene silencing efficiency of LP-LNPs prepared by the lipopeptide provided in Experimental Example 1 of the present invention and the auxiliary lipid 14PA in delivering siCCNB1 to A549 cells.
[0025] Fig.10 C provided in Experimental Example 1 of the present invention 10 -KH 2 Statistical graph of gene silencing efficiency of siRNA delivered by / DOTAP to A549, Hela, 4T1 and MCF-7 cells.
[0026] Fig.11 C provided in Experimental Example 1 of the present invention 10 -KH 2 Inverted fluorescence microscopy images of GFP gene expression after DOTAP delivery of GFP-mRNA to A549, MCF-7, CHO, Vero, HEK 293T, PC 12, Hela, RAW264.7 and 4T1 cells.
[0027] Fig.12 C provided in Experimental Example 1 of the present invention 10 -KH 2 / DOTAP delivery of GFP-mRNA to A549, MCF-7, CHO, Vero, HEK 293T, PC 12, Hela, RAW264.7 and 4T1 cells.
[0028] Fig.13 This is a bar graph showing the relative expression levels of the PTEN gene in the heart, liver, spleen, lung and kidney tissues of mice 48 hours after siPTEN was delivered to mice by LP-LNPs provided in Experimental Example 2 of the present invention.
[0029] Fig.14 This is a bioluminescence image of the heart, liver, spleen, lung, and kidney tissues of mice 6 hours after the LP-LNPs provided in Experimental Example 2 of the present invention delivered Luciferase-mRNA into the mouse body.
[0030] Fig.15 This is a bar graph of the average luminescence intensity of the mouse heart, liver, spleen, lung, and kidney tissues 6 hours after the LP-LNP provided in Experimental Example 2 of the present invention delivered Luciferase-mRNA to the mouse. DETAILED DESCRIPTION
[0031] In order to make the purpose, technical scheme and advantages of the present invention clearer, the technical scheme of the present invention will be clearly and completely described below in conjunction with the drawings in the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present invention. The following embodiments are used to illustrate the present invention, but cannot be used to limit the scope of the present invention.
[0032] A lipopeptide, wherein the lipopeptide is a compound formed by a ring-opening reaction between a 1,2-epoxy compound and part or all of the exposed amino groups of a lysine-histidine polypeptide; Wherein, the structural formula of the lipopeptide is: or .
[0033] Preferably, the 1,2-epoxy compound comprises 2 to 22 carbon atoms.
[0034] Preferably, the 1,2-epoxy compound is any one of 1,2-epoxy-9-decene, 1,2-epoxydecane, 1,2-epoxydodecane, 1,2-epoxytetradecane and 1,2-epoxyoctadecane.
[0035] Preferably, in the lipopeptide structural formula, the value range of x is 0-10, the value range of y is 1-10, the value range of n is 1-5, and the value range of m is 0-5.
[0036] Preferably, R is any one of the following structural formulas, or R is hydrogen and at least one R is any one of the following structural formulas: , , , and .
[0037] A method for preparing a lipopeptide, for preparing the lipopeptide, comprises the following steps: S101. Under the protection of an inert gas, add a lysine-histidine polypeptide and 1,2-epoxide to a reaction solvent, and stir at a temperature of 50° C. to 110° C. for 48 h to 72 h to prepare a mixture; S102, purifying the mixture to prepare the lipopeptide.
[0038] A lipopeptide-based lipid nano-delivery system, comprising the lipopeptide, and further comprising one of cholesterol and a cholesterol derivative, an auxiliary lipid and a PEGylated lipid; The molar ratio of lipopeptide, cholesterol or cholesterol derivative, auxiliary lipid and pegylated lipid is (5-45):(25-40):(25-65):(0.8-2.5).
[0039] Preferably, the helper lipid is at least one of a cationic lipid, an anionic lipid, a phospholipid and a phospholipid derivative; The PEGylated lipid is at least one of PEG-DMG, PEG-C-DMG and PEG-DSPE.
[0040] An application of a lipopeptide-based lipid nano-delivery system is used to prepare lipopeptide-based lipid nano-particles. The lipopeptide-based lipid nano-particles comprise the lipopeptide-based lipid nano-delivery system and RNA molecules.
[0041] Preferably, the RNA molecule is at least one of messenger RNA, small interfering RNA, micro RNA and self-amplifying RNA; and the mass ratio of the lipopeptide-based lipid nano-delivery system to the RNA molecule is 40 to 10:1.
[0042] The present invention will be further described below with reference to specific embodiments and experimental examples.
[0043] In the following examples, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all available from commercial sources unless otherwise specified.
[0044] Example 1 Preparation of lipopeptides.
[0045] In N 2 Lysine-histidine peptide and 1,2-epoxide were added to a 10 mL pressure bottle under protection. The formulations and amounts of different lysine-histidine peptides and 1,2-epoxides are shown in Table 1. The reaction solvent is methanol. The amount added is preferably 2 ml. After stirring at 90°C for 96 h, the reaction was stopped to prepare 25 different lipopeptides as shown in Table 2. The obtained reaction mixture was purified by dialysis (for in vitro application) or silica gel column chromatography (eluent: dichloromethane: methanol = 20:1) 2:1) (when used in vivo), the lipopeptides were obtained. The yields of 25 different lipopeptides are shown in Table 3.
[0046] Among them, different lysine-histidine polypeptide amino acid sequences are represented as follows: SEQ ID NO.1 is: KH-NH 2 ; SEQ ID NO.2 is: KKHH-NH 2 ; SEQ ID NO.3 is: KKKHHH-NH 2 ; SEQ ID NO.4 is: KKKKHHHH-NH 2 ; SEQ ID NO.5 is: KHHKHHKHHKHH-NH 2 .
[0047] Table 1 Composition of 25 different lipopeptides Table 2 25 different lipopeptides prepared Table 3 Yields of 25 different lipopeptides after purification
[0048] Example 2 Preparation of lipopeptide-based lipid nanoparticles.
[0049] RNA molecules are mixed with a lipopeptide-based lipid nano-delivery system to obtain RNA-encapsulated nanoparticles, namely lipopeptide-based lipid nanoparticles. The preparation process is as follows: The 25 lipopeptides, auxiliary lipids, cholesterol and DMG-PEG 2000 prepared in Example 1 were dissolved in anhydrous ethanol. In the in vitro application, the mass ratio of lipopeptide, auxiliary lipid, cholesterol and DMG-PEG 2000 was 9.5:8.5:3:1; in the in vivo application, the molar ratio of lipopeptide, auxiliary lipid, cholesterol and DMG-PEG 2000 was 25:45:28.5:1.5. The auxiliary lipid added was cationic liposome 1,2-dioleoyl-3-trimethylammonium propane (abbreviated as DOTAP), zwitterionic liposome 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine (abbreviated as DOPE), zwitterionic liposome 1,2-distearoyl-sn-glycero-3-phosphocholine (abbreviated as DSPC) or anionic liposome 1,2-dimyristoyl-sn-glycero-3-phosphate (abbreviated as 14PA).
[0050] RNA molecules (siRNA or mRNA) are dissolved in a citric acid-sodium citrate enzyme inactivation buffer at pH = 3 to prepare an aqueous phase. The aqueous phase and the organic phase are mixed manually or by microfluidics at a ratio of 3:1 (v / v), and the mass ratio of the lipopeptide-based lipid nanodelivery system to the RNA molecule is preferably 20:1, so that lipopeptide-based lipid nanoparticles (LP-LNPs) can be prepared, which are denoted as lipopeptide / helper lipid, such as C 10 -KH 2 / DOTAP, C 10 -KH 4 / DOPE, C 10 -KH 4 / DOPE, C 18 -KH 4 / DOPE, not listed here one by one. Figure 1 C 10 -KH 2 / Transmission electron micrograph of DOTAP.
[0051] The obtained LP-LNPs can be directly used for characterization experiments and in vitro applications. For in vivo applications, the prepared LP-LNPs were dialyzed against 1× PBS in a dialysis cassette with a molecular weight cutoff of 3500 Da at 4°C for 2 hours before use.
[0052] Example 3 Characterization of lipopeptide-based lipid nanoparticles.
[0053] The particle size, polymer dispersity index (PDI) and Zeta potential of the LP-LNPs samples prepared by manual mixing in Example 2 were measured using a Malvern laser particle size analyzer. The measurement results are shown in Tables 4 and 5.
[0054] It can be seen from Tables 4 and 5 that the particle size of the LP-LNPs samples obtained by manual mixing is between 59 nm and 361 nm, and the Zeta potential is between -5.6 mV and 3.8 mV.
[0055] Table 4
[0056] Table 5
[0057] Experimental Example 1 In vitro cell experiment.
[0058] 1. Cell culture: The cells are cultured in a complete culture medium containing fetal bovine serum; the volume fraction of the fetal bovine serum in the complete culture medium is preferably 10%; the culture conditions are preferably continuous culture in an incubator at 37° C. containing 5% carbon dioxide by volume.
[0059] 2. Cytotoxicity test: The CCK-8 kit was used to evaluate the cytotoxicity of LP-LNPs. The specific process was as follows: lung cancer A549 cells were plated at 1×10 4 The cells were inoculated in a 96-well culture plate at a density of 10 μg / mL and placed in an incubator at 37°C with 5% carbon dioxide for 24 h. When the cell confluence reached 80% to 90%, LP-LNPs at a concentration of 10 μg / mL and commercial transfection reagent Lipofectamine 2000 at a concentration of 0.75 μg / mL were added. TM After 24 h of co-culture with cells, 10 μL of CCK-8 reagent was added to each well. The mixture was incubated at 37°C for 2 hours. The absorbance of each well at 450 nm was then measured using an ELISA reader. The cell viability was calculated using the following formula: Cell survival rate (%) = [(As-Ab) / (Ac-Ab) ] x 100; As, Ac and Ab represent the absorbance of the sample, control well and blank well, respectively. Each experiment was repeated three times. TM The 24 h toxicity results on A549 cells are as follows Figures 2 to 5 shown.
[0060] 3. Determination of gene silencing efficiency of siRNA delivered by LP-LNPs in vitro (siRNA@LP-LNPs).
[0061] A549, MCF-7, Hela, RAW264.7 and 4T1 cells were plated at 2x10 per well. 5 The cells were inoculated in a 24-well culture plate at a density of 1.5 μg / mL and placed in an incubator at 37°C with a volume fraction of 5% carbon dioxide for 24 hours until the cell confluence reached 60% to 80%. The complete culture medium was replaced with the minimum essential medium (MEM medium) containing siRNA@LP-LNPs (at a concentration of 10 μg / mL) (0.5 μg siRNA per well). After 4 hours of transfection, the complete culture medium was replaced with the complete culture medium for 48 hours. RNA was then extracted for qPCR to detect the expression level of the target gene relative to the housekeeping gene to evaluate the efficiency of LP-LNPs in delivering siRNA. (The siRNA transfection reagent for the control group was Lipofectamine 2000 TM , Lipofectamine 2000 TM Use according to the instructions, the dosage is 1.5μL / well.) The results of the test are as follows Figures 6 to 10 As shown, the results showed that LP-LNPs can effectively deliver siRNA to a variety of cell lines and achieve high gene silencing efficiency. 10 -KH 2 / DOTAP delivered siRNA to A549, RAW264.7, Hela, 4T1 and MCF-7 cells, achieving target gene silencing efficiencies of 96%, 93.5%, 92.2%, 95.4% and 72.3%, respectively, which were significantly higher than the commercial transfection reagent Lipofectamine 2000. TM Gene silencing efficiency achieved in the above cells.
[0062] 4. Determination of the gene expression efficiency of green fluorescent protein mRNA (GFP-mRNA) (GFP-mRNA@LP-LNPs) delivered by LP-LNPs in vitro.
[0063] A549, MCF-7, CHO, HEK 293T, PC 12, Hela, RAW264.7 and 4T1 cells were cultured at 2x10 cells per well. 5The cells were inoculated in a 24-well culture plate at a density of 5% carbon dioxide in an incubator at 37°C for 24 hours, and the cell confluence reached 60% to 80%. The complete culture medium was replaced with MEM culture medium (containing 1 μg siRNA per well) containing GFP-mRNA@LP-LNPs (concentration of 10 μg / mL). After 4 hours of transfection, the complete culture medium was replaced with a continuous culture medium for 48 hours. The efficiency of LP-LNPs delivering mRNA was then evaluated by characterization using an inverted fluorescence microscope and flow cytometer. (The siRNA transfection reagent for the control group was Lipofectamine 2000 TM , Lipofectamine 2000 TM Use according to the instructions, the dosage is 1.5μL.) The results of the test are as follows Fig.11 and Fig.12 The results show that LP-LNPs can effectively deliver mRNA to a variety of cell lines and achieve high gene expression efficiency. 10 -KH 2 / DOTAP delivered GFP-mRNA to Hela, CHO, A549, HEK 293T, PC12, 4T1, MCF-7, and RAW264.7 cells, achieving 95.3%, 98.7%, 96.8%, 92.2%, 85.0%, 83.9%, 72.5%, and 78.6% GFP expression positive rates, respectively, which were significantly higher than those of the commercial transfection reagent Lipofectamine 2000. TM The GFP expression positive rate achieved in the above cells.
[0064] Experiment 2 In vivo animal experiment.
[0065] 1. Delivery of siPTEN by LP-LNPs into mice.
[0066] C 10 -KH 2 / DOTAP, C 10 -KH 4 / DOPE and C 18 -KH 4 The complex of DOPE and siPTEN (10 μg) was injected into C57BL / 6 mice (20 g) through the tail vein. The mice were killed and dissected 48 hours later. The heart, liver, spleen, lung, and kidney of the mice were separated, and RNA was extracted from each tissue. The expression level of the target gene PTEN relative to the housekeeping gene GAPDH in each tissue was detected by qPCR to evaluate the efficiency of LP-LNPs in vivo delivery of siRNA.
[0067] Test results such as Fig.13As shown, the results show that C 10 -KH 2 / DOTAP, C 10 -KH 4 / DOPE and C 18 -KH 4 / DOPE highly selectively delivered siPTEN to the lung, liver, and spleen target tissues, respectively, and achieved target gene silencing efficiencies of 76.9%, 79.2%, and 76.3% in the corresponding target tissues, respectively.
[0068] 2. In vivo delivery of firefly luciferase mRNA (Luciferase-mRNA) by LP-LNPs into mice.
[0069] C 10 -KH 2 / DOTAP, C 10 -KH 4 / DOPE and C 18 -KH 4 The assembled complex of / DSPC and Luc-mRNA (15 μg) was injected into C57BL / 6 mice (20 g) through the tail vein. Six hours later, 200 μL of luciferase substrate d-luciferin at a concentration of 20 mg / mL was injected into the mouse peritoneum. Fifteen minutes later, the mice were killed and dissected to separate the main organs of the mice, including the heart, liver, spleen, lung, and kidney. The organs were imaged using a small animal in vivo imager (animal 3D imager, PerkinElmer, USA). The imaging results are shown in the figure. Fig.14 , Fig.15 shown.
[0070] The results showed that C 10 -KH 2 / DOTAP, C 10 -KH 4 / DOPE and C 18 -KH 4 Luciferase-mRNA delivered by DSPCE was selectively and efficiently expressed in the lung, liver and spleen target tissues, respectively. The average luminescence intensity (p / sec / cm 2 / sr) are 2.8x10 6 , 7.9 x10 5 and 4.8 x10 4 Therefore, it is possible to achieve the purpose of precise delivery of RNA molecules to multiple organs in vivo. 10 -KH 2 / DOTAP has better selectivity and higher transfection efficiency for lung tissue.
[0071] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A lipopeptide, It is characterized in that The lipopeptide is a compound formed by a ring-opening reaction between a 1,2-epoxy compound and part or all of the exposed amino groups of a lysine-histidine polypeptide; Wherein, the structural formula of the lipopeptide is: or .
2. The lipopeptide according to claim 1, It is characterized in that The 1,2-epoxy compound includes 2 to 22 carbon atoms.
3. The lipopeptide according to claim 2, It is characterized in that The 1,2-epoxy compound is any one of 1,2-epoxy-9-decene, 1,2-epoxydecane, 1,2-epoxydodecane, 1,2-epoxytetradecane and 1,2-epoxyoctadecane.
4. The lipopeptide according to claim 1, It is characterized in that In the lipopeptide structural formula, the value range of x is 0-10, the value range of y is 1-10, the value range of n is 1-5, and the value range of m is 0-5.
5. The lipopeptide according to claim 1, It is characterized in that In the lipopeptide structural formula, R is any one of the following structural formulas, or R is hydrogen and at least one R is any one of the following structural formulas: 、 、 、 and .
6. A method for preparing a lipopeptide, It is characterized in that For preparing the lipopeptide according to any one of claims 1 to 5, comprising the following steps: S101. Under the protection of an inert gas, add a lysine-histidine polypeptide and 1,2-epoxide to a reaction solvent, and stir at a temperature of 50° C. to 110° C. for 48 h to 72 h to prepare a mixture; S102, purifying the mixture to prepare the lipopeptide.
7. A lipopeptide-based lipid nano-delivery system, It is characterized in that The lipopeptide according to any one of claims 1 to 5, further comprising one of cholesterol and cholesterol derivatives, a helper lipid and a PEGylated lipid; The molar ratio of lipopeptide, cholesterol or cholesterol derivative, auxiliary lipid and pegylated lipid is (5-45):(25-40):(25-65):(0.8-2.5).
8. A lipopeptide-based lipid nano-delivery system as claimed in claim 7, It is characterized in that The auxiliary lipid is at least one of a cationic lipid, an anionic lipid, a phospholipid and a phospholipid derivative; The PEGylated lipid is at least one of PEG-DMG, PEG-C-DMG and PEG-DSPE.
9. Application of a lipopeptide-based lipid nano-delivery system, It is characterized in that Used for preparing lipopeptide-based lipid nanoparticles, the lipopeptide-based lipid nanoparticles include the lipopeptide-based lipid nano delivery system as described in claims 7 and 8 and RNA molecules.
10. Use of the lipopeptide-based lipid nano-delivery system as claimed in claim 9, It is characterized in that The RNA molecule is at least one of messenger RNA, small interfering RNA, micro RNA and self-amplifying RNA; the mass ratio of the lipopeptide-based lipid nano-delivery system to the RNA molecule is 40 to 10:1.
Citation Information
Patent Citations
Non-viral gene delivery agent comprising lipopeptide (LP) compounds
CN110769862A
Nucleic acid delivery system based on alkylated polypeptide as well as preparation method and application
CN113563429A
Lipopeptides, nanoparticles and methods of use
US20240327457A1
Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (CTL) epitopes
WO2004014957A1
Lipopeptides for delivery of nucleic acids
WO2009046220A2
Cited By
Functional lipopeptide, preparation method thereof, functional lipopeptide-assisted nucleic acid drug lipid nano-delivery system and application of functional lipopeptide-assisted nucleic acid drug lipid nano-delivery system
CN121627824A
